Updated Sep 18, 2024
In This Section |
This section contains the following topics:
|
1. General Information on and Establishment of Claims Based on Participation in CBRNE Testing
Introduction |
|
This topic contains general information as well as establishment procedures for claims based on participation in CBRNE testing, including
|
Change Date |
July 29, 2021
|
VIII.iii.5.A.1.a. Definition: CBRNE Claims |
|
Chemical, Biological, Radiological, Nuclear, and Explosives (CBRNE) claims are claims in which a Veteran claims that a disease or injury resulted from participation in any test, chemical or biological, regardless of location, other than those tests discussed at M21-1, Part VIII, Subpart iii, 6.A and tests involving mustard gas.
Examples: Exposures during tests conducted at
Important: While the examples listed above are known test locations, other areas of exposure likely exist.
|
VIII.iii.5.A.1.b. Action to Take When the Veteran Claims Participation in CBRNE Testing but Does Not Claim a Disability |
|
A claim is not substantially complete if a Veteran alleges participation in CBRNE testing during service, but does not claim service connection (SC) for a specific disability. In cases such as these, follow the procedures for handling an incomplete application at M21-1, Part II, Subpart iii, 1.C.2.b and c.
|
VIII.iii.5.A.1.c. EP Control Procedures for Claims Based on CBRNE Testing |
|
Upon receipt of a substantially complete CBRNE claim for SC, establish a traditional rating end product (EP) (for example, 010, 110, 020) and affix the ChemBio special issue indicator to the relevant contention(s).
Reference: For more information on EP control, see M21-4, Appendix B, Section II.
|
Introduction |
|
This topic contains information on developing claims based on CBRNE testing, including
|
Change Date |
September 18, 2024
|
VIII.iii.5.A.2.a. Researching Exposure in ILER |
|
The Individual Longitudinal Exposure Record (ILER) is a joint Department of Defense (DoD) and VA web-based application that provides the ability to link a Veteran to military exposures and/or deployments.
Claims processors must utilize ILER to conduct preliminary research regarding claimed in-service chemical and biological agent testing-related exposures.
Important: ILER access should be requested in advance of receipt of a claim based on exposure in order to ensure that claims processing is not unnecessarily delayed.
Reference: For more information on ILER and how to obtain access, see the ILER Guidance.
|
VIII.iii.5.A.2.b. Procedure for Verifying Participation in CBRNE Testing |
|
Follow the steps in the table below to verify participation in CBRNE testing.
Important:
|
VIII.iii.5.A.2.d. Information to Include in Examination and/or Medical Opinion Requests for Claims Based on CBRNE Testing |
|
The Veterans Health Administration has prepared Under Secretary for Health Information Letter, 10-2006-010, Potential Health Effects Among Veterans Involved in Military Chemical Agent Experiments Conducted from 1955 to 1975, to address questions about the potential health effects to Veterans involved in the testing of warfare agents. The letter should be brought to the examiner’s attention either on the examination request or in information placed in the claims folder.
When requesting an examination, also include in the Remarks section of the examination request a list of the agents, simulants, tracers, antidotes and other such substances, as applicable, to which Compensation Service has verified exposure for the Veteran or as shown in ILER.
When requesting a medical opinion as to whether there is a relationship between a disease or disability and participation in CBRNE testing during service, identify for the examiner’s review the exposure information obtained from ILER or provided in response to the request under M21-1, Part VIII, Subpart iii, 5.A.2.b.
Important: When requesting an examination and/or medical opinion for claims based on CBRNE testing, ensure the examiner is provided with the claims folder for consideration.
Reference: For more information on the requirement to identify relevant evidence for the examiner’s review, see M21-1, Part IV, Subpart i, 2.A.8.d.
|